BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)


| Study or Subgroup | Sacubitril/valsartan Events | Sacubitril/valsartan Total | Control Events | Control Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| **1.5.1 All HFrEF patients** | | | | | | |
| AWAKE-HF 2019 | 0 | 69 | 1 | 70 | 0.1% | 0.34 [0.01, 8.16] |
| CLCZ696B2223 | 0 | 8 | 0 | 8 | | Not estimable |
| EVALUTE-HF 2019 | 1 | 231 | 1 | 232 | 0.1% | 1.00 [0.06, 15.96] |
| **Subtotal (95% CI)** | | **308** | | **310** | **0.2%** | **0.63 [0.08, 5.07]** |
| Total events | 1 | | 2 | | | |
| Heterogeneity: Tau² = 0.00; Chi² = 0.26, df = 1 (P = 0.61); I² = 0% | | | | | | |
| Test for overall effect: Z = 0.44 (P = 0.66) | | | | | | |
| **1.5.2 Guideline recommended** | | | | | | |
| Li J 2019 (1) | 3 | 62 | 5 | 64 | 0.4% | 0.62 [0.15, 2.48] |
| OUTSTEP-HF | 1 | 309 | 4 | 310 | 0.2% | 0.25 [0.03, 2.23] |
| PARADIGM-HF 2014 | 729 | 4203 | 848 | 4229 | 99.2% | 0.86 [0.79, 0.95] |
| PRIME-HF 2019 | 1 | 60 | 0 | 58 | 0.1% | 2.90 [0.12, 69.81] |
| **Subtotal (95% CI)** | | **4634** | | **4661** | **99.8%** | **0.86 [0.79, 0.94]** |
| Total events | 734 | | 857 | | | |
| Heterogeneity: Tau² = 0.00; Chi² = 2.01, df = 3 (P = 0.57); I² = 0% | | | | | | |
| Test for overall effect: Z = 3.25 (P = 0.001) | | | | | | |
| **Total (95% CI)** | | **4942** | | **4971** | **100.0%** | **0.86 [0.79, 0.94]** |
| Total events | 735 | | 859 | | | |
| Heterogeneity: Tau² = 0.00; Chi² = 2.35, df = 5 (P = 0.80); I² = 0% | | | | | | |
| Test for overall effect: Z = 3.26 (P = 0.001) | | | | | | |
| Test for subgroup differences: Chi² = 0.09, df = 1 (P = 0.77), I² = 0% | | | | | | |